Poly ICLC clinical trials
Also written Hiltonol and NSC-301463.
How each study uses poly ICLC is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the poly ICLC studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Development codes
- NSC-301463
- 2
Studies by the year they started
61 studies that test it; most in 2014 (7)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 54
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Washington University School of Medicine (4) · Dana-Farber Cancer Institute (3) · Rockefeller University (3) · Patrick Ott, MD, PhD (2) · Roswell Park Cancer Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Nina Bhardwaj (2)
Often tested with
Tested in the same studies.
flt3 ligand protein (5) · NeoVax (4) · Rasdegafusp alfa (4) · CDX-301 (3) · Peptides (2) · IMA950 (2) · Protein Subunit Vaccines (2) · CDX-1140 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test poly ICLC.
- Dec 2026Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active SurveillancePhase 2 · Ashutosh Kumar Tewari
- Jan 2027In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsPhase 1 · University of Southern California
- Jul 2027A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.Phase 1 · Dana-Farber Cancer Institute
- Oct 2027Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerPhase 1 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Nov 2027Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerPhase 1 · Fred Hutchinson Cancer Center
Studies
Open first, then newest update. How each study uses poly ICLC is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 61
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingPhase 1Fred Hutchinson Cancer CenterNCT05098210Written as Poly ICLC
- A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingPhase 1Dana-Farber Cancer InstituteNCT03219450Written as NeoVax
- Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active SurveillanceRecruitingPhase 2Ashutosh Kumar TewariNCT06343077Written as Poly-ICLC intramuscular (IM) injection
- Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryActive, not recruitingPhase 1Washington University School of MedicineNCT05111353Written as Poly-ICLC
- NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04024878Written as NeoVax
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05013216Written as Cohort A: Patients at high risk of developing pancreatic cancer.
- Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaActive, not recruitingPhase 1Adilia HormigoNCT03223103Written as Poly-ICLC
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingPhase 1University of Southern CaliforniaNCT04616248Written as Poly ICLC
- Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedPhase 1/2Icahn School of Medicine at Mount SinaiNCT03789097Written as Poly ICLC
- ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBMActive, not recruitingPhase 1Mustafa Khasraw, MBChB, MD, FRCP, FRACPNCT05283109Written as Hiltonol
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04930783Written as NEOVAX
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT03358719Written as Poly ICLC
- NeoVax Plus Ipilimumab in Renal Cell CarcinomaActive, not recruitingPhase 1Patrick Ott, MD, PhDNCT02950766Written as NeoVax
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaCompletedPhase 1Patrick Ott, MD, PhDNCT01970358Written as Poly-ICLC
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedPhase 1Craig L Slingluff, JrNCT04116320Written as Poly ICLC
- Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedPhase 1/2University Hospital, GenevaNCT03665545Written as IMA950/Poly-ICLC
- A Phase II Trial of Poly-ICLC for Low-Grade GliomasTerminatedPhase 2University of Alabama at BirminghamNCT04544007Written as Poly ICLC
- Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedPhase 1/2Stemline Therapeutics, Inc.NCT02078648Written as SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
- A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric GliomasCompletedPhase 1James FelkerNCT01130077Written as Poly-ICLC
- Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLCWithdrawnPhase 1/2VA Office of Research and DevelopmentNCT06064279Written as Poly ICLC
See all 61 studies that test poly ICLC →
Given beside what is tested · 30 — poly ICLC is usual care or a partner of the new treatment
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Poly ICLC
- Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNot yet recruitingPhase 1Washington University School of MedicineNCT07300475Written as poly-ICLC
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingPhase 1Finn, Olivera, PhDNCT06218303Written as Hiltonol®
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseRecruitingPhase 1Washington University School of MedicineNCT06529822Written as Poly ICLC
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06411691Written as KRAS Vaccine with Poly-ICLC adjuvant
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT03206047Written as Poly ICLC
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMActive, not recruitingPhase 1Massachusetts General HospitalNCT02886065Written as Hiltonol
- Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmActive, not recruitingPhase 1Marina KremyanskayaNCT05025488Written as Poly ICLC
- Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT04201873Written as Poly ICLC
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT02287428Written as Poly-ICLC
- A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric GliomaActive, not recruitingPhase 1Jonsson Comprehensive Cancer CenterNCT06342908Written as Poly ICLC
- The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.Active, not recruitingPhase 1Ashutosh Kumar TewariNCT05010200Written as Poly-ICLC
- Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive, not recruitingPhase 1Massachusetts General HospitalNCT02826434Written as Hiltonol
- Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnPhase 1Jonsson Comprehensive Cancer CenterNCT05457959Written as Poly ICLC
- Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant ChemotherapyTerminatedPhase 1Washington University School of MedicineNCT03956056Written as Poly ICLC
- Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaTerminatedPhase 1Washington University School of MedicineNCT03121677Written as Poly ICLC
- Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial CancerCompletedPhase 1Matthew GalskyNCT03359239Written as Poly ICLC
- A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma RecurrenceCompletedPhase 2Nina BhardwajNCT02334735Written as Poly-ICLC
- Neoadjuvant Hiltonol® (PolyICLC) for Prostate CancerCompletedPhase 1Ashutosh Kumar TewariNCT03262103Written as Intratumoral (IT) Poly ICLC 1.0 mg
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT01834248Written as Poly ICLC
Showing 20 of 30.
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryNov 3, 2026NCT05111353
Codes
What other systems call poly ICLC · ClinicalTrials.gg INT002713
- MeSH (NLM) C019531poly ICLCConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7KYP9TKT70HILTONOLConfirmed FDA, NLM
- NCI Thesaurus C1198Poly ICLCOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C019531 | poly ICLC | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7KYP9TKT70 | HILTONOL | Confirmed FDA, NLM |
| NCI Thesaurus | C1198 | Poly ICLC | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.